Product Description
Akros Pharma was developing jtt-302, an oral CETP Inhibitor for Dyslipidemia. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT00748852)
Mechanisms of Action: CETP Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Akros Pharma
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Dyslipidemia
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| AT302-U-06-004 | P2 |
Completed |
Dyslipidemia |
2008-03-01 |
2019-03-18 |
Treatments |
|
| AT302-U-06-003 | P2 |
Completed |
Dyslipidemia |
2008-02-01 |
2019-03-18 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|